epitheliotropic intestinal T-cell lymphoma (MEITL), are frequently found along the gastrointestinal (GI) tract and are known to be more aggressive, with patients experiencing bleak clinical outcomes [1] . While this might indicate a sitespecific preference in the formation and progression of TNKLs, the molecular biology underlying such preference has not been fully elucidated. In this study, we sought to investigate genetic alterations in primary GI-TNKLs in a comparative manner to characterize the molecular features thereof and to gain insights into the site-specific tumorigenesis of TNKLs.
From Severance Hospital Cancer Registry data, 18 primary GI-TNKLs were collected: GI-TNKL was defined according to the definitions proposed by Lewin et al. and the fourth revision of World Health Organization classification [1, 2] . The 18 cases consisted of six MEITLs, six ENKTLs, three anaplastic large cell lymphomas, and three intestinal T-cell lymphomas not otherwise specified (ITCL-NOS). In addition, 28 cases of non-GI-TNKL were collected for comparative analysis. The complete list of samples, clinical/pathological features, and overall workflow for sample collection are described in the accompanying Supplementary Data (Supplementary Tables 1 and 2 , Supplementary Figures 1-3 , and Supplementary Appendix).
Initially, we conducted whole-exome sequencing (WES) analysis for six GI-TNKL samples (three MEITLs and three ENKTLs) to obtain a rough profile of somatic mutations. After assessment of the data quality (Supplementary  Table 3 ), we applied the Genome Analysis Toolkit best practice pipeline on the WES data to discover somatic variants (Supplementary Figure 4 and Supplementary Appendix) and identified 230 genes with somatic mutations. We also conducted a literature survey to obtain additional gene variants: mutations in 187 lymphoma-related genes were reported in previous genomic studies (Supplementary Figure 5A) . Finally, we constructed a targeted panel of 417 genes for deeper analysis of GI-and non-GI-TNKLs (Supplementary Table 4 ).
Using the targeted panel, we conducted deep targeted sequencing (~900×) for 46 TNKL samples (18 GI-and 28 non-GI-TNKLs) (Supplementary Figure 5B and Supplementary Appendix). At this stage, we applied more stringent filtering for genes from large public germline databases and frequent false positive genes (referred to as "blacklist" genes) ( Tables 6 and 7) . We assumed that a high mutation load (8.02/Mb) resulted from the targeted sequencing. Mutation spectrums, base-substitution frequency (C > T enriched), and Ti/Tv ratio (~2.6) were similar between GI-and non-GI-TNKLs and reflected the typical characteristics of cancers ( Supplementary Figures 6 and 7) .
Inspecting the genetic landscape of nonsynonymous mutations (Fig. 1a) , we discovered that TET2 was the most
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Non-GI-TNKL (n = 28) KCNB2   KCNH8   JAK3   JAK1   JAK2   TYK2   KCNJ12   IGSF10   IGSF9   G14  G05  G16  G18  G01  G11  G03  G04  G13  G09  G10  G02  G07  G17  G06  G08  G12  G15  N46  N76  N64  N75  N23  N26  N68  N52  N55  N70  N11  N12  N14  N22  N28  N31  N36  N38  N40  N41  N43  N44  N48  N51  N60  N66  N69  N73   JAK-STAT  pathway   Potassium  voltage-Gated  Channel   Immunoglobulin  superfamily   22%   11%   11%   0%   0%   4%   28%   17%   0%   0%   0%   0%   4%   7%   22%   6%   0%   0%   N11  N43  N48  N38  N69  N40  N68  G08  N66  G15  N51  N41  N36  N14  N44  G14  N22  N73  N23  N70  N52  N60  N28  N12  G01  N64  N31  G10  N75  G17  G18  G02  N46  N55  G07  G03  G13  G04  G09  G06  N26  G05  G11  G16  G12  N76   TET2   CSMD3  CSMD2  FSIP2  TP53   SETD2  ZBTB7C  AIM1  EIF3A  LAMC3  MGA  NWD2  SGK223  ZFHX4  CCDC40  DDX3X  KAT6B  TDRD7  ARID1B  ATM  BCOR  CD22  CHD8  CLTCL1  CUL9  DNAH12  DNMT3A  FBN2  JAK3  KRAS  NOTCH1  PRDM1  ROBO2  SMARCA4  TET1   COL24A1   33%  22%  20%  20%  20%  17%  17%  17%  15%  15%  15%  15%  15%  15%  15%  13%  13%  13%  13%  11%  11%  11%  11%  11%  11%  11%  11%  11%  11%  11%  11%  11%  11%  11%  11% frequently mutated gene in all TNKL samples (15/46, 33%), followed by CSMD3 (10/46, 22%), CSMD2 (10/46, 20%), FSIP2 (10/46, 20%), and TP53 (9/46, 20%). Frequent indels, nonsense mutations, and splice site variants in TET2 (10/15, 66%) and TP53 (4/9, 44%) implied that mutations in these tumor suppressor genes may act in a loss-of-function manner. SETD2 mutations were also observed in 17% of samples, corresponding to previous reports [3] . We further analyzed the site-specificity of the detected mutations (Fig. 1b) . While previously known mutant genes were highly present in non-GI-TNKLs (46, 32, and 25% for TET2, CSMD3, and CSMD2, respectively), we were able to find a few novel mutations enriched in GI-TNKLs that are important in three different biological functions: the voltage-gated potassium (Kv + ) channel, the JAK-STAT pathway, and the immunoglobulin superfamily (see below). With regard to Kv + channel pathway genes, eight mutations (seven missense and one nonsense single nucleotide variants) in KCNB2 (4/18, 22%), KCNH8 (2/18, 11%), and KCNJ12 (2/18, 11%) were discovered in six GI-TNKL samples. These genes encode Kv + channel proteins that mediate transmembrane potassium transport in excitable membranes, which is primarily activated in brain and smooth muscle cells of the GI-tract [4] . Further analysis demonstrated that the KCNB2 mutations were located in the ion transport and Kv2 channel domains (Fig. 2a) . In silico protein modeling and multiple sequence alignment predicted that one of the KCNB2 mutations (Arg307Cys) results in a critical defect in the function of voltage-gated channels (Supplementary Figures 8, 9 and Supplementary Appendix), while the others remained inconclusive. Compared to normal tonsil tissue, non-GI-TNKL tissue, and GI-TNKL tissue with wild-type KCNB2, GI-TNKL tissue with KCNB2 mutation exhibited lower levels of KCNB2 mRNA upon reverse transcription PCR, although statistical significance was not observed (Supplementary Figure 10 and Supplementary Appendix). Immunohistochemical protein expression was correlated with mRNA expression of KCNB2. Also, low expression of KCNB2 protein was found to be related with an inferior overall survival rate in systemic mature T-and NK-cell lymphomas regardless of GI or non-GI site (Supplementary Table 8 , Supplementary Figure 11 and Supplementary Appendix).
Associations between altered regulation of the Kv + channel and cancer development have been continuously reported, such as mutations of KCNH1 in breast cancer and acute myeloid leukemia [5, 6] , of KCNH2 in glioblastoma [7] , and of KCNA3 in pancreatic cancer [8] . In T cells, aberrations of Kv + channels have been shown to induce changes in intracellular K + and Ca + concentrations and to impair T-cell receptor-driven Akt-mTOR signaling and Ca2 + signaling pathways, thereby triggering T-cell activation [9] . In addition, such aberrations may induce a blockade of T-cell effector function by eliciting an ionic checkpoint, which results in immune suppression within the tumor microenvironment [9] . Thus, we conjectured that the newly found mutations in the Kv + channel family genes might be a potential driving mechanism of T-cell lymphoma and cancer immunity. Moreover, we suspect that the sitespecificity of the mutations may mirror differences in the tumor microenvironment, considering the known functional roles of Kv + channels in the GI tract, including electrolyte and substrate transport, cell migration, cell proliferation, and apoptosis [10] . The JAK-STAT pathway is a well-known mutation target in systematic TNKLs [11] [12] [13] [14] . In the present study, mutations in the JAK-STAT pathway showed GI specificity by presenting only in JAK3 (5/18, 28%) and JAK1 (3/18, 17%). Most previous studies have reported JAK2 mutations only. The newly found JAK3 and JAK1 mutations were located in the pseudokinase and kinase domains (Fig. 2a) . Further, we found more GI-specific mutations in the downstream genes of JAK-STAT pathways, including STAT1, PTPN11, and SOS1, which might indicate GI-TNKL-specific aberrations in the pathway (Fig. 2b ). Although further study should follow, these findings suggest that differences in the tumor microenvironment might be related with the vulnerability of GI-TNKLs to genetic mutations in JAK3 and JAK1.
Mutations in IGSF9 (1/18, 6%) and IGSF10 (4/18, 22%), members of the immunoglobulin superfamily, were found exclusively in GI-TNKLs. So far, no strong associations have been reported between immunoglobulin function and TNKLs, except one recent study that showed a recurrent IGSF10 mutation in familial gastric and colorectal cancer [15] . We expect that further in-depth studies can test the vulnerability of resident cells, such as mucosa epithelial cells and immune T cells, in the milieu of the GI-tract to IGSF10 mutations.
Finally, we conducted direct Sanger sequencing to confirm the presence of mutations in KCNB2, JAK3, and JAK1 (Supplementary Table 9 and Supplementary Appendix). In seven cases in which genomic DNA were available, nine mutations were validated (Supplementary Figure 12 and Supplementary Appendix).
In conclusion, we noted characteristic mutations of KCNB2, as well as JAK3, JAK1, and IGSF10, in GITNKLs. Although more comprehensive work is needed, the present findings provide some insights into understanding the physiological and pathological links between these genes and GI-TNKL genesis and into the potential for targeted therapy against tumor cells and the tumor microenvironment associated therewith. To the Editor:
Chronic lymphocytic leukemia (CLL) displays remarkable clinical heterogeneity, likely attributed to the underlying biological diversity [1] . This claim is supported by the fact that certain immunogenetic and/or genomic features identify subgroups of CLL patients with distinct prognosis and outcome [2] [3] [4] . Indeed, determination of the somatic hypermutation (SHM) status of the immunoglobulin heavy variable (IGHV) genes expressed by the clonotypic B cell receptor (BcR) and screening for aberrations οf the TP53 gene are nowadays considered essential for clinical decision making [5] . A cautionary note appears warranted when utilizing biomarkers, where the prognosis is usually assessed assuming stable predictability over the disease course; this hypothesis, however, is often unrealistic as it concerns genomic aberrations [6, 7] . Therefore, arguably, the prognostic power of a given biomarker may, instead, heavily depend on the time distance from diagnosis.
To address this issue we investigated in early-stage CLL patients the impact over-time of SHM within the IGHV genes, i.e., the segregation into mutated (M-CLL) and unmutated CLL (U-CLL), on the evolution of risk for CLL progression and need of treatment. Our analysis was based on hazard curves instead of Kaplan-Meier survival curves, which represent, respectively, the "instant" risk for the event at each time-point instead of the cumulative risk [8, 9] .
Overall, 1900 early-stage, Binet A CLL patients from 10 European institutions diagnosed according to the 2008 iwCLL criteria [10] were included in this retrospective study (summary of patient characteristics: Supplemental Table 1 ). Ethical approval was granted by the local review committees and informed consent was collected according to the Helsinki Declaration.
Fluorescence in situ hybridization (FISH) was performed in 1476/1900 (77.7%) cases using probes for the 13q14, 11q22, 17p13 regions and trisomy 12; results were interpreted following Döhner's hierarchical model [11] . Genes analyzed for mutations included TP53 (exons 4-10, n = 1186/1900, 62.4%), SF3B1 (exons 14-16, n = 1166/ 1900, 61.4%) and NOTCH1 (entire exon 34 or targeted analysis for del7544-45/p.P2514Rfs*4, n = 1691/1900, 89%). Sequence analysis of IGHV/IGHD/IGHJ rearrangements was performed in all cases as described [12] . All FISH, gene mutation screens and IG gene sequencing studies were performed once before the administration of any treatment; in 1702/1900 (90%) cases, these tests were performed within the first year from diagnosis.
In order to assess the risk for disease progression, we evaluated the time-to-first-treatment from diagnosis within different genomic subgroups, with risk evolution over-time represented by a hazard curve. Smoothed estimates of the hazard curve were computed separately for M-CLL and U-CLL, based on a non-parametric methodology ("bshazard" package) [13] .
To compare the evolution pattern of hazard curves for each subgroup, we investigated over-time both their differences and ratios. Years 5, 10, and 15 after diagnosis were considered as landmark time-points for over-time comparison. The distributions of hazard differences were statistically compared between consecutive 5-year intervals to Fig. 1 Standard Kaplan-Meier survival plot and hazard plot for the entire cohort and the TP53abn patients. The hazard plot shows the estimated proportion of patients who received treatment for the first time in a defined time interval, given that they were still treatment-free at the start of this interval. The p-value corresponding to the log-rank test for the comparison of the survival distributions is displayed in the survival plot. The table including the number of patients at risk, and the cumulative number of events/censoring, applies in both plots. For both subgroups, the survival curves (a, c) exhibited a similar behavior. When considering the hazard curves (b, d), M-CLL showed a gradual decrease in both subgroups, while U-CLL exhibited significant differences over-time with a constant decrease over-time in the entire cohort (b) and initial decrease until the fifth year and sudden increase for the TP53abn patients (d) assess the evolution over-time (trend) of the distance between the hazard curves of the M-CLL and U-CLL patients. p-values less than 0.05 might indicate convergence or divergence of the curves within consecutive 5-year intervals. Regarding the hazard ratios for M-CLL and U-CLL, the proportional hazards assumption was checked. Moreover, a method able to identify the break points in the hazard was applied ("RPEXE.RPEXT" package) [14] . The analysis was performed with R. Details about the statistical methodology are provided in Supplemental Material.
Based on the SHM status, 1224 (64.4%) and 676 (35.6%) patients were classified as M-CLL and U-CLL, respectively. The over-time risk for evolution was evaluated with SHM status as a reference using hazard plots in: (i) the entire cohort, (ii) cases with TP53 In both the entire cohort and TP53abn patients, M-CLL exhibited gradual risk decrease over-time (Figs. 1b, d ). In contrast, in U-CLL, a constant decrease was observed in the entire cohort, while in TP53abn cases the hazard curve initially decreased until the fifth year and then started to increase, indicating intensification of the risk for progression after the fifth year (Figs. 1b, d) . Notably, the survival plots (Figs. 1a, c) failed to highlight any difference regarding the over-time risk between M-CLL and U-CLL and exhibited a similar behavior with slowly increasing distance between the M-CLL and U-CLL survival curves over-time.
In the remaining cases (Supplemental Fig. 1-5 ), the M-CLL hazard curve slowly decreased except for del [11q] patients. In U-CLL, there was a wide range for hazard evolution: from decrease, such as for patients with del[13q]/ normal FISH), del[11q], and NOTCH1 mutations; to almost stable hazard over-time (SF3B1 mutant patients). Interestingly, +12 patients showed a risk evolution similar to cases with TP53abn.
Regarding the distribution of hazard differences, significant differences were found in the entire cohort between M-CLL and U-CLL in all consecutive pairs of 5-year intervals with p Figure 7A ) reflecting a statistically significant decrease of the distance between the two hazard curves in all pairwise comparisons. The same evolution rule was followed by the del[13q]/normal-FISH patients as well as patients carrying del[11q] or NOTCH1 mutations (Supplemental Figures 7D, 7B, 7E ). For patients with SF3B1 mutations, the distance between the two curves remained almost stable, p [0,5]Vs (5, 10] = 0.465 (Supplemental Figure 7F ). In sharp contrast, within TP53abn patients, the distance between the hazard curves for M-CLL and U-CLL increased significantly after the 5th year with p [0,5]Vs(5,10] = 0.006 (Fig. 2a) . Similarly, in +12 patients, the U-CLL hazard curve constantly increased from diagnosis, with p [0,5]Vs(5,10] = 0.006 (Supplemental Figure 7C ).
Next, we tested the proportional hazards assumption (see Supplemental Table 2 , Supplemental Figure 9 ) to test whether the hazard ratio between an U-CLL and an M-CLL patient depended on time. The assumption was rejected only for the TP53abn patients (p-value = 0.045), reflecting the great variation observed with hazard ratios ranging from 1.75 to 8.09.
We then introduced a novel tool to visualize the comparison of risk evolution between M-CLL and U-CLL patients, per subgroup, in terms of both the hazard differences and ratios. A characteristic example concerns TP53abn patients (Fig. 2b) , where the hazard ratio of U-CLL to M-CLL increased linearly before and Fig. 2 Hazard plot and evolution of hazard differences/ratios for the TP53abn patients. a The hazard plot shows the estimated proportion of patients who received treatment for the first time in a defined time interval, given that they were still treatment-free at the start of this interval. The hazard differences between the M-CLL and U-CLL curves are represented by vertical dashed lines. The p-value of the comparison within consecutive 5-year intervals of the distributions of hazard differences between M-CLL and U-CLL is also displayed. b The evolution of the hazard difference, U-CLL-M-CLL, with its scale displayed in the left vertical axis in red, and the evolution of the hazard ratio, U-CLL/M-CLL, with its scale displayed in the right vertical axis in black, are simultaneously displayed for the TP53abn patients exponentially after the 5th year. Moreover, amongst TP53abn cases, both the differences and the ratios exhibited the most pronounced change of all the subgroups considered with ranges 0.22 and 6.33, respectively. TP53abn and +12 patients (Supplemental Figure 8C) were the only subgroups where both the differences and the ratios increased monotonically over-time, reflecting the divergence of the hazard curves. By applying piecewise exponential distribution no breakpoints were observed.
The concept of hazard curves [15] has not been yet explored in CLL. The principal advantage of a hazard curve compared to the standard Kaplan-Meier survival curve is that it represents the "instant" risk for the event of interest at each time-point, instead of the cumulative risk until that point. This might prove important in CLL, where, typically, the prognostic power of any biomarker is assumed stable over the disease course, although this is often unrealistic concerning genomic aberrations. Hence, it is crucial to evaluate the temporal effect on the factors' prognostic power regarding CLL progression.
Our approach was grounded on the fundamental segregation of CLL patients into M-CLL and U-CLL, since the SHM status remains stable over-time; [1] furthermore, M-CLL and U-CLL have distinct biological background underlying distinct clonal behavior and eventual outcome [1, 12] . Within each subgroup we assessed how time distance from diagnosis impacted the prognostic power of several biomarkers on CLL progression. Taking a step further, we proposed a new method to statistically evaluate the differences in risk evolution between these patient groups.
In M-CLL, the risk for disease evolution was rather homogeneous across different genomic subgroups, tending to gradually decrease over-time. In contrast, within U-CLL the pattern of over-time risk evolution was remarkably heterogeneous, greatly affected by the genomic background of the malignant clone. In particular, TP53abn cases exhibited a significant increase of disease evolution especially after the 5th year from diagnosis (further highlighted by the rejection of the proportional hazards assumption). A similar pattern was observed in +12 cases. A possible explanation for the hazard increase amongst U-CLL cases with TP53abn and +12 may relate to either the expansion of the clonal size over-time or the acquisition of extra genomic abrnormalities, reflecting potential genomic instability.
In conclusion, differential patterns of risk evolution for disease progression in M-CLL versus U-CLL support the notion that the SHM status represents more than a simple prognostic/predictive marker, and that segregation of CLL patients based on SHM might aid to detect important time effects on risk evolution within genomic subgroups of CLL patients. Moreover, they imply that specific genomic abnormalities may be linked to differential risk for disease progression over-time, while their prognostic impact may be modulated with the time elapsing from the initial diagnosis. This new methodology for evaluating and visualizing the over-time risk for disease evolution in CLL is easy to apply and can be generalized to cover the case of scoring systems where the number of categories compared is more than two, arguably also in other disease contexts. To the Editor:
Juvenile myelomonocytic leukemia (JMML) is a lifethreatening myeloproliferative neoplasm of early childhood [1] originating from multipotent hematopoietic stem/progenitor cells [2] that requires allogeneic hematopoietic stem cell transplantation (HSCT) in the majority of cases [3] . We and others have linked the clinical picture and prognosis of JMML to differential DNA methylation patterns in leukemic cells [4] [5] [6] [7] . A retrospective case series documented that treatment with the DNA methyltransferase-inhibiting agent azacitidine achieved complete clinical and molecular remissions in children diagnosed with JMML, suggesting superior therapeutic potential of this drug [8] . To generate a preclinical research model for JMML, we have previously established a xenotransplantation system of this leukemia in Rag2
. Transplantation of primary JMML cells resulted in stable xenologous engraftment, reproduced a characteristic JMML phenotype, and sustained serial transplantations for up to 1.5 years [9] . Here we used the xenotransplantation system to study if leukemia-initiating cells determine the aberrant DNA methylation profiles in JMML. We then investigated the antileukemic activity of azacitidine in JMML xenografts in comparison to the cytostatic agent, cytosine arabinoside (cytarabine). The latter is used for cytoreduction in JMML but lacks the ability to induce complete remissions [3] . Xenotransplantations were prepared by irradiating neonatal Rag2
-/-BALB/c mice sublethally with 2.5 Gy. Six hours later, 1 × 10 6 CD3-depleted JMML mononuclear cells suspended in 30 µl of phosphate-buffered saline were injected intrahepatically. Histopathological examination of experimental animals, isolation of human cells from murine organs, and evaluation of cell populations by flow cytometry were These authors contributed equally: Miriam Erlacher, Christian Flotho performed as previously described [9] . The experiments were approved by local authorities and complied with the German law for animal protection (Tierversuchsgesetz).
We first tested the hypothesis that the aberrant DNA methylation patterns observed in mature JMML cell progeny originate in leukemic stem cells. We used leukemia cell samples isolated from spleens of three children with JMML (Supplementary Table 1 ) to initiate the disease in immunodeficient mice and compare DNA methylation profiles between the original patient samples and a total of 13 xenografts. Hematopoietic cell populations were assessed by flow cytometry in patient samples and corresponding xenografts, demonstrating similar leukemia immunophenotypes (Fig. 1a) . Infinium 450K arrays were used for the genome-wide analysis of CpG methylation in primary JMML cells and xenografts. The technical reliability was assessed by processing three cell aliquots from the same clinical sample on separate arrays and was extraordinarily high (R 2 coefficients >0.99, Supplementary Figure 1 ). We found that the epigenomes of JMML cells were highly robust, with only minimal alteration induced by the xenotransplantation procedure (Fig. 1b) . On average, 0.36% of 29,938 promoters and 0.44% of 29,765 intragenic regions were called as "differentially methylated" between source and xenograft (change in β-value >0.2, p <0.05 adjusted for false discovery rate). These results provide compelling evidence that the DNA methylation patterns of JMML cells repopulating the murine bone marrow are programmed in the leukemia-initiating cell. The analysis was extended by combining the methylome data of the three patient samples and 13 primary xenografts with methylome data of two secondary xenografts derived from patient #1 after serial retransplantation, and two tertiary xenografts derived from patient #2. Unsupervised clustering of~5000 CpG sites with most variable methylation in JMML resulted in a dendrogram where all xenotransplanted leukemias associated with their original patient sample (Fig. 1c) . Together, the data indicate that xenotransplanted JMML-initiating cells faithfully reproduce the epigenetic make-up of the original leukemia.
We next xenotransplanted 50 mice with JMML cells from the three patients (Supplementary Figure 2) and compared the effects of treatment with azacitidine 3 mg/kg/ d or cytarabine 20 mg/kg/d on xenografted JMML (5 days on and 9 days off, two cycles). Stable body weight indicated that the treatment was generally tolerated well by the experimental animals (Supplementary Figure 3) . Cytarabine and azacitidine led to mild anemia and moderate thrombocytopenia in the mice compared to mock treatment (Supplementary Figure 4 ). Azacitidine strongly reduced the level of infiltration by human JMML cells in all organs analyzed (Fig. 2a, b) . The effect was most pronounced in spleen (human CD45
+ fraction of all CD45 + cells, 0.2% ± 0.04% versus 22.5% ± 5.8% in mice injected with saline; p < 0.0001) and lung (0.4% ± 0.12% versus 21.6% ± 4.5%; p < 0.0001) but significant also in bone marrow and liver. The splenomegaly caused by xenotransplantation of cells from patients JMML#1 and JMML#2 reverted to near-normal under treatment with azacitidine. Treatment with cytarabine reduced the human cell infiltration in murine organs to a similar degree. Importantly, however, we noted that CD34 + stem/progenitor cells within the human leukemia population were substantially reduced in the murine bone marrow after treatment with azacitidine (20.2% ± 7.3% versus 39.4% ± 3.5% in mice injected with saline; p < 0.01) but not cytarabine (35.6% ± 6.11%) ( (Fig. 2d) , with the vast majority of CpG sites being either unmethylated or completely methylated. The JMML cell samples obtained after treatment with azacitidine displayed dramatic global DNA demethylation with a complete loss of fully methylated CpG sites (Fig. 2d) . However, enrichment analyses of demethylated enhancers or promoters failed to point out cellular components or pathways that might be specifically derepressed by azacitidine. + cells extracted from bone marrow of xenotransplanted mice at 9-36 weeks after transplantation (Y-axis). DNA methylation was analyzed using Infinium Human Methylation 450K Bead Chip arrays (Illumina) as previously described [5] . The RnBeads software package was used for data normalization, filtering of single-nucleotide polymorphisms, removal of probes on sex chromosomes, and quantification. The plots were created with ggplot2 (version 2. We then tested if the reduction of leukemic stem/progenitor cells by azacitidine was functionally relevant. After treating JMML xenograft mice with two cycles of azacitidine, cytarabine, or saline solution, the murine bone marrow was transplanted into secondary recipient mice to assess its capacity to reinitiate the leukemia. We found that Table 2) . By contrast, JMML cells from primary recipients treated with cytarabine engrafted in eight of 13 secondary mice (p = 0.03, Fisher exact test). Of note, there was no difference in secondary engraftment between JMML cells treated with cytarabine and those treated with saline. Collectively, the retransplantation experiments provide in vivo evidence that azacitidine is more effective than cytarabine for targeting leukemia-initiating cells in JMML, despite the structural similarity of both compounds as cytosine nucleoside analogs. Low-dose azacitidine has shown promising clinical activity in children diagnosed with JMML [8] , corresponding to its potent antileukemic effect in the xenotransplantation model. Consistent with our repopulation assays, azacitidine was reported to support remissions for up to 11 months in patients [8] . However, we do not expect monotherapy with azacitidine to be eventually curative for JMML, similar to observations for other malignant myeloid disorders [10] . An attractive perspective would be the use of azacitidine before HSCT with the aim of reducing both the relapse rate and the risks involved with the transplant procedure. Whether this concept works out in reality is open. The ongoing industry-sponsored Pediatric Investigation Plan for the prospective evaluation of azacitidine in children with JMML before HSCT (EudraCT number 2014-002388-13, ClinicalTrials.gov identifier NCT02447666) will help answer these questions.
The precise mechanism of the antineoplastic activity of azacitidine is incompletely understood. The methylome data of xenotransplanted JMML cells exposed to azacitidine demonstrate that this substance exerts effective inhibition of DNA methyltransferases in JMML cells and shifts the widespread CpG island hypermethylation back toward normal levels. However, the precise genes where this effect is relevant have yet to be defined. In addition, azacitidine induced genome-wide hypomethylation at sites where cytosine methylation is physiologic. Previous landmark studies have highlighted the profound consequences of demethylating repetitive DNA elements and long terminal repeats, resulting in activation of endogenous retroviral double-stranded RNA sequences [11, 12] and production of irregular RNA transcripts [13] . A concept with increasing popularity in the field stipulates that the expression of neoantigens and production of aberrant peptides following treatment with DNA-hypomethylating agents enhances the autologous anti-tumor immune response [14, 15] . It is an interesting discussion point in this regard that azacitidine was highly effective against JMML in our xenotransplantation model even though the host animals lacked functional T, B, or NK cells.
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Nilotinib, a second-generation tyrosine kinase inhibitor (TKI), has been described to be a superior drug in the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) [1] . However, with more mature follow-up, it has become clear that nilotinib is associated with impaired glucose and lipid metabolism [2] [3] [4] and an excess in arterial thrombotic events in comparison to imatinib [5] . The 5-year safety update of the ENESTnd trial [3] provided further confirmation; it reported significant elevations in fasting glucose and serum lipids and an increased incidence of cardiovascular events in nilotinib-treated patients as opposed to imatinib [3] . Adipose tissue is an important determinant of whole body glucose and lipid homeostasis [6] , and adipocyte dysregulation is known to result in various metabolic abnormalities [7] . Accumulation of drugs in adipose tissue could result in adipocyte toxicity; we have shown that anti-HIV drugs cause adipocyte toxicity leading to insulin resistance and the development of cardiometabolic disease in HIV-positive individuals [8] . We hypothesised that nilotinib could cause adipocyte toxicity leading to various metabolic adverse effects in CML patients; here we have undertaken a translational study using in vitro-in vivo models to characterise this. We have also tested telmisartan, an angiotensin receptor blocker (ARB) and antihypertensive with beneficial metabolic effects [9] , as a potential therapeutic strategy to reduce nilotinib-induced metabolic toxicity in vitro.
A chronic in vitro toxicity model as previously described [8] , consisting of 3T3-F442A murine preadipocyte cells, was used to investigate the effect of nilotinib and imatinib on adipocytes. Briefly, differentiating adipocytes were incubated with either nilotinib (with or without telmisartan) or imatinib 48 h post-initiation of differentiation, and drug treatment was continued every 48 hours over a period of 10 days to mimic the chronic dosing schedule in CML patients. Nilotinib (1-4 μM) and imatinib (5 μM) were used within their therapeutic range; given the lipophilicity of nilotinib, we also assessed a hypothetical higher nilotinib concentration (20 μM) assuming adipose tissue accumulation following chronic drug treatment. Lopinavir, an anti-HIV drug known to cause adipocyte toxicity and metabolic disturbances [8] , was used as positive control. We have only investigated these two TKIs in the current study. Statistical analyses were conducted by one-way ANOVA with Dunnett's Test. All in vitro experiments were repeated three times in triplicate. A p value ≤ 0.05 was considered significant.
We investigated whether nilotinib and/or imatinib (0.01-100 µM) caused cytotoxicity in both undifferentiated and differentiating adipocytes using the MTT assay. Neither nilotinib nor imatinib reduced cell viability in these cell types at clinically relevant concentrations (Supplementary Figure 1) . We hypothesised that nilotinib may interfere with adipocyte lipid accumulation and alter mRNA levels of key adipogenic regulatory genes (Pparγ, Lpin1, Srebp1). Lipid accumulation in differentiated adipocytes was assessed on day 10 using Oil Red O staining [8] and gene expression was assessed by RealTime PCR using Taqman assays (Life Technologies). Nilotinib (4 µM: 0.46 absorbance units±0.02, p = 0.001), but not imatinib, caused dose-dependent reduction in adipocyte lipid accumulation when compared with the vehicle (0.56 ± 0.01) ( Fig. 1A ; also see Supplementary Figure 2 ). Reduced lipid droplet formation observed with nilotinib may suggest the inability of adipose tissue to store lipids; this will result in the ectopic accumulation of fat in the liver and skeletal muscle leading to the development of insulin resistance [10] . Nilotinib, but not imatinib, also resulted in dose-dependent downregulation of all three adipogenic regulatory genes, with the effect evident at therapeutic concentrations (4 µM nilotinib: Ppar-γ: 48% downregulation, Lpin1: 40% downregulation, Srebp1: 29% downregulation; all p < 0.05; Fig. 1B ). PPARγ is a master regulator of adipogenesis and mediates adipogenic gene expression and insulin sensitivity [11] ; lipin1, a gene that . Telmisartan was coincubated with only one concentration of nilotinib (4 µM). Lopinavir (LPV), an anti-HIV drug, was used as a positive control. All experiments were repeated three times in triplicate. Statistical analyses were conducted by one-way ANOVA with Dunnett's Test. Data represent Mean ± SD; p ≤ 0.05. *Vehicle vs NILO/LPV/IMA; † NILO4µM vs NILO4µM + TEL5µM. NILO: nilotinib, IMA: imatinib, TEL: telmisartan, LPV: lopinavir, Hprt: Hypoxanthinephosphoribosyltransferase Letterencodes a magnesium-ion-dependent phosphatidic acid phosphohydrolase enzyme, is involved in triglyceride synthesis [12] ; SREBP1 plays a role in cholesterol homeostasis [13] . We then assessed the effect of these two TKIs on Glut4, the principal glucose transporter in the adipocyte; both nilotinib (p = 0.01), and to a lesser extent imatinib (p = 0.02), significantly downregulated Glut4 mRNA expression in differentiating adipocytes (Fig. 1B) . Downregulation of Glut4 by nilotinib could result in reduced glucose uptake into the adipocyte and may lead to insulin resistance observed in CML patients. Downregulation of Glut4 by imatinib, a drug that has been consistently suggested to improve insulin sensitivity in CML patients [14] , is interesting; this suggests the need to assess other mechanisms involved in the regulation of whole body insulin sensitivity, such as the role of liver and skeletal muscle. We then assessed whether telmisartan can reverse nilotinib-induced adipocyte toxicity; co-incubation of telmisartan (5 µM) with 4 µM nilotinib resulted in significant reversal of nilotinib-mediated inhibition of adipocyte lipid accumulation (NILO + TEL: 0.52 ± 0.01, in comparison to NILO 4 µM: 0.46 ± 0.02, p = 0.01; Fig. 1A ) and adipogenic mRNA downregulation (p = 0.02; Fig. 1B) .
Next, we investigated whether TKIs affect adiponectin in vitro and in plasma samples obtained from CML patients. Adiponectin is a protein exclusively secreted by the adipocyte and is a key mediator of systemic insulin sensitivity and glucose homeostasis [6] . Total adiponectin in the conditioned media collected from drug-treated and control adipocytes were measured using a standard ELISA. Nilotinib induced a dose-dependent reduction in adiponectin secretion (4 µM: 20% reduction, p = 0.02); however, the effect of imatinib was only marginal (9.9% reduction, p = 0.04). Interestingly, co-incubation of telmisartan with nilotinib reversed the inhibitory effect of nilotinib on adiponectin secretion in vitro (p = 0.001; Fig. 2A ).
For the in vivo analysis of adiponectin, nonfasted plasma samples at three different time points (baseline, 3 and 12 months) were obtained from 30 CML patients who received either nilotinib (n = 14) or imatinib (n = 16) for at least 12 months. Relevant ethics approval and patient consent were obtained. All patients were in first chronic phase throughout. In the nilotinib-treated group, six patients received the drug as first-line therapy and eight as second line following initial treatment with imatinib. Five out of the eight second-line nilotinib patients were imatinib-resistant and showed higher BCR-ABL1 transcript levels at the time of the switch; the remaining three were switched due to imatinib intolerance. In all second-line nilotinib patients, the sample collected at the time of initiation of nilotinib therapy was considered as the baseline sample. All patients in the imatinibtreated group received the drug as first-line. We did not have baseline sample for one of the imatinib-treated patients, therefore we excluded that patient from any analysis (i.e. imatinib, final n = 15). The median ages of imatinib and nilotinib-treated CML patients were 39 and 49 years, respectively; both drug groups had eight female subjects each. None of the patients recruited had a medical history of diabetes. Total adiponectin was measured using an electrochemiluminiscence-based sandwich immunoassay (Meso Scale Discovery, USA). Repeated measures ANOVA with Dunnett's Test was used to compare adiponectin levels at different time points. Imatinib resulted in a significant increase in plasma adiponectin levels at 3 (38.4 ± 7.1 mg/l; p < 0.01) and 12 month (36.7 ± 7.2 mg/l; p < 0.01) time points compared with baseline values (27.3 ± 5.7 mg/l; p < 0.05; Fig. 2B ). By contrast, in both first-line (Fig. 2C ) and second-line (Fig. 2D) nilotinib patients, there was no change in adiponectin concentrations; however, with second-line nilotinib, there was a non-significant decrease at both 3 (15.2 ± 1.8 mg/l; p = NS) and 12 months (14.6 ± 1.7 mg/l; p = NS; Fig. 2D ) when compared to baseline levels (21.3 mg/l).
Nilotinib-induced reduction in adiponectin in vitro was, to a certain extent, mirrored in the CML plasma samples obtained from second-line nilotinib-treated CML patients, but this was non-significant. However, it should be noted that our sample size was small (n = 14 or 15 per drug group) and therefore lacked sufficient power to detect a statistically significant difference in adiponectin. On the other hand, the increase in plasma adiponectin observed with imatinib correlates with what has been previously reported for imatinib in CML patients [14] . Adiponectin expression is directly regulated by PPARγ [6] ; it is possible that nilotinib-induced reduction in adiponectin could be a direct result of the downregulation of PPARγ by nilotinib. The molecular mechanism(s) by which imatinib increases adiponectin secretion is not clear; it is also possible that the increase in adiponectin levels observed with imatinib in vivo could be a mere reflection of improvement in general health in CML patients.
Here we have shown that repeated exposure of nilotinib and imatinib has contrasting effects on adipocyte lipid accumulation, adipogenic mRNA expression and secretion of adiponectin. Together, these mechanisms may explain the impaired glucose and lipid metabolism observed in nilotinibtreated CML patients. Although aggressive screening for cardiovascular risk factors and cardiometabolic surveillance in CML patients has been suggested to reduce nilotinibrelated cardiometabolic events [15] , there is also a need for therapeutic preventive strategies. The reversal of nilotinibinduced adipocyte toxicity by telmisartan in vitro is important in this context. The metabolic beneficial effects of telmisartan have been suggested to be due to both PPARγ agonism [8] and angiotensin receptor blockade; the potential therapeutic utility of telmisartan to counter the deleterious cardiometabolic adverse effects caused by nilotinib in CML patients will now need to be evaluated by observational, as well as randomised studies. Our in vivo study has some major limitations, such as small sample size, nonavailability of fasting plasma samples and lack of complete concurrent clinical data; future studies will need to address these limitations and validate these results to obtain a better understanding of nilotinib-induced metabolic adverse effects.
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To the Editor:
There are unsolved questions in the field of minimal/ measurable residual disease (MRD) detection by multiparameter flow cytometry (MFC) in acute myeloblastic leukemia (AML). One of them, the value of peripheral blood (PB) testing, is raised repeatedly [1] . A Pubmed search on the topic is, however, exceedingly frustrating and mostly retrieves publications based on the morphological assessment of blast cells in PB [2] [3] [4] . The 2007 study by Maurillo et al. [5] was the first to propose pertinent MFC data. In this work, 50 and 48 patients, respectively, were studied in MFC for matched samples of PB and bone marrow (BM) after induction and consolidation of a chemotherapy regimen. At that time, all post-induction PB and BM samples contained detectable MRD. However, the 10 patients who had no detectable PB MRD after consolidation had a significantly better outcome, highlighting the potential value of PB MRD. In 2009, very early detection of peripheral blasts in MFC during the first days of induction was also shown to be of high prognostic value [6] , a result confirmed by Yu et al. in 2015 [7] . The second most pertinent work of MRD during and after chemotherapy appeared in Leukemia in 2016, from the Dutch group HOVON [8] . The relevance of MRD assessment in PB on survival was confirmed there on a larger series of 76 evaluable patients. Among them, at a threshold of 0.04% established by ROC curves, respectively, 9/55 and 2/29 patients had detectable PB MRD after induction and consolidation. Their outcome was significantly poorer than that of MRD-negative patients. A good correlation was also noted with BM MRD.
In the course of a multicenter research program on AML MRD that was supported by the French Institute of Cancer (Inca), peripheral blood (PB) sampling was recommended for an ancillary investigation, besides that of classical bone marrow (BM) assessment. Results of the latter have been published recently [9] , detailing the types of patients and treatments received. This work demonstrated the robustness of a novel analysis algorithm using a patienttailored protocol established with MFC data of the diagnosis and a fixed set of monoclonal antibodies. Being then directly applied to the same patient's follow-up samples, this protocol allowed to detect MRD down to a level of 5 × 10 −5 . Patients who never had an MRD above this threshold during follow-up fared significantly better than those having at least one "positive" follow-up sample.
Here we report the application of the same strategy for the 96 patients of this cohort who also benefited from PB sampling and who are representative of the whole 256 cohort. PB samples were treated and analyzed exactly as the BM samples, as reported [9] , in a lysis-no-wash approach and the recommendation to acquire at least 250,000 events.
Failure to detect more than 10 suspect immunophenotypically clustered events (usually none at all) led to the conclusion of "undetectable" MRD. All analyses were performed blinded of the results of BM MRD data. The diagnosis listmodes of each patient were completely reinterpreted to establish the appropriate patient-specific protocol. Overall, 217 follow-up samples were analyzed, respectively, 66 post-induction, 55 before the second consolidation, 35 at the end of treatment, and 61 at later timepoints. MRD was found to be always negative for 67 patients, while it was always positive for 25. For the remaining four patients, MRD became negative for three and all ultimately relapsed. These patients were pooled with the group of MRD-positive patients, compared to the truly "always negative" mentioned above.
Event-free survival was assessed from the date of complete remission until relapse, death, or last news. Overall survival was assessed from the date of complete remission until death or last news. Fig. 1b) . The dates of sample collection were too heterogeneous to test other time-points in this "real life" collection of data (i.e., independent of any clinical trial), yet the same prognostic value was observed. We also tested other thresholds which, as for the BM study of the same cohort, demonstrated the clear superiority of "undetectable" MRD at the 5 × 10 −5 sensitivity.
Agreement between PB and BM results was investigated for 213 matched samples available. For 144 pairs of them, both PB and BM were always negative, and for 54 both pairs were always positive. The remaining 15 samples has no detectable PB MRD while it was positive in BM. This resulted in a specificity and positive predictive value of 100%, while sensitivity was 78% and the negative predictive value 91%.
In conclusion, this multicenter study confirms the robustness and universal applicability of the limited panel used, where the relevant myeloid markers are CD34, CD117, CD33 and CD13, CD15, and CD7 being less informative [9] . Of course, an initial CD45 gating is crucial to properly identify the progenitor population. This is consistent with the recently published consensus of the European LeukemiaNet [1] . As suggested by the studies analyzing the rate of blast decrease in PB during the first days of induction chemotherapy [2-4, 6, 7] , this work confirms the importance of a rapid clearance of the tumor bulk. Indeed, the best prognosis is definitely obtained for patients with undetectable MRD as early as at the first point of investigation, who then retain negative MRD. PB is more easily available than BM and simpler to analyze because there are no normal progenitors in such samples. It could thus be suggested to perform MRD detection in PB in order to reinforce therapy in case of positivity. BM MRD could thus become necessary only in case of PB negativity, to secure the good response of individual patients.
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Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which immunoglobulin-derived serum M-protein is produced by a plasma cell clone and is detectable in the blood [1] . MGUS resembles multiple myeloma (MM), but antibody levels and number of plasma cells in the bone marrow are lower, and it is generally asymptomatic and often diagnosed idiosyncratically. However, since MGUS can lead to MM, which develops at the rate of 0.5-1.5% a year, yearly monitoring is generally recommended [2] . The prevalence of MGUS increases from age 50 onwards (1.7% at 50-59 years), reaching 6.6% by age over 80 years according to a literature review [2] . As the cumulative incidence of MM by age 75 years in Sweden is 0.4% for men and 0.3% for women, it is clear that the prevalence of MGUS far exceeds that of MM (NORDCAN database http://www-dep.iarc.fr/NORDCAN/FI/frame.asp). Genome-wide association studies (GWASs) have so far identified common genetic variants at 23 loci associated with MM risk [3] . Thus far the role of genetic variation influencing MGUS has only been studied to a limited extent [4] . Some of the first reported MM risk loci have in two early studies been shown to be at least weakly associated with MGUS [5] . To more comprehensively address the genetics of MGUS and its relationship to MM we conducted a GWAS of MGUS by analyzing 992 patients and 2900 controls.
Detailed methods are described in the Supplement. We studied three independent sets of MGUS patients and controls. The German GWAS comprised 243 MGUS cases and 1285 controls [4] . The Czech GWAS was based on 288 cases and 600 controls. The Swedish MGUS included 461 patients and 1025 controls. Odds ratios (ORs) for singlenucleotide polymorphism (SNP) associations in the three populations were meta-analyzed using PLINK software v1.90. Differences in the associations between MGUS and MM were tested using ASSET as previously [5] . The most promising MGUS associations were tested in the metaanalysis of the German population of 1717 MM cases and 2069 controls and the UK population of 2282 MM cases and 5197 controls; a recent study describing 23 genomewide significant loci for MM [3, 6] .
A Manhattan plot of GWAS on MGUS highlights 10 loci reaching a meta p-value below 10 −5 ( Supplementary Figure 1) . The meta ORs for the risk allele ranged from 1.28 to 1.48 and the smallest p-value reached 5.6 × 10 −7 for locus 3p22.1 (rs9848754, ULK4) ( Table 1) . With the exception of this locus and the locus at 17p11.2 (rs74998556, TNFRSF13B), the other eight loci were unique to MGUS when compared to MM (95% confidence intervals (CIs) were non-overlapping). A similar conclusion was reached by the ASSET analysis, displaying MGUS on eight SNPs as positive and MM data as null or negative (Supplementary Figure 2) . None of the signals from the three MGUS sample sets showed significant heterogeneity (p het and I 2 statistic, Supplementary Table 2 were subjected to ASSET analysis, and as expected all MM associations were classified as positive (Supplementary Figure 3) . Among MGUS SNPs, 16 were also classified as positive, 4 as null (rs6595443, rs17507636, rs13338946, and rs877529), and 3 as negative (rs7193541, rs6066835, and rs138740) ( Table 2 , column "MGUS OR"). Only for rs6066835 and rs138740 the 95% CIs did not overlap between MGUS and MM.
The results are summarized in Supplementary Figure 4 for each of the 31 loci. The 8 MGUS-specific loci are marked with stars. Functional considerations of the associated SNPs are based on data from the available annotation tools (Supplement).
In the interpretation of the genetic profiles between the two plasma cell dyscrasias one needs to consider the prevalence of these conditions, MGUS being more than 10 times more common than MM. Thus, a higher OR for a SNP in MGUS compared to MM may imply that the related gene predisposes to MGUS but does not contribute to progression to the end disease. If the OR for the SNP is increased to an equal extent in MGUS and MM, the SNP is likely to be predisposing equally to MGUS and to the end disease. If the risk is increased only in MM the related gene is likely to be predisposing to it. A large difference between the risk for MGUS and the end disease may indicate selection towards the risk genotype. A limitation of the study is that we have longitudinal follow-up data for a relatively short time not allowing flagging of the MGUS cases developing MM.
Applying these guidelines, and keeping in mind the caveat of limited sample sizes, the data suggest eight loci to be specific to MGUS. These included four loci, which marked genes SGMS2, RIMS2, and TSNARE1, and one with limited biological data. The four other loci marked genes that had known functions in cancer: PROX1, SFMBT, Table 1 Meta-analyzed odds ratios for the most significant MGUS SNPs (p < 10 Table 2 Published multiple myeloma risk loci in MGUS meta-analysis , and CSNK1G1. PROX1 interacts with GATA2, an important regulator of hematopoiesis and roles in predisposition to myelodysplastic syndrome/acute myeloid leukemia [7] . SFMBT is a polycomb group epigenetic regulator with suggested functions in prostate cancer. The DNA repair gene RAD51C has been associated with germline mutations in common cancers [8, 9] . Casein kinase 1 gamma 1 isoforms contribute plasma cell survival [10] [11] [12] . According to the above convention these genes may be important in MGUS but the variants are selected against during progression to the end diseases. The second group of SNPs was shared by the two dyscrasias and ORs tended to be higher in MGUS than in MM. These included SNPs marking DTNB, a gene encoding a component of the dystrophin-associated protein complex, ULK4, encoding a key regulator of mTOR-mediated autophagy [13] , and TNFRSF13B encoding a key regulator of B-and T-cell functions with involvement in pathophysiology of MM [14] . The association of rs4487645 (IRF4-binding site) was weaker for MGUS than for MM while for rs11086029 (19p13.11, KLF2) the association was slightly higher. The data suggest that the underlying gene functions are vital for MGUS and MM but they appear most important for the end disease.
As the final group, the SNPs marked by genes, PREX1 and TOM1, were not MGUS related. However, it is intriguing that PREX1 appeared as a major interacting partner when genome-wide two gene interactions were tested in MGUS [15] ; in the same study TOM1L1, an analog of TOM1 was also a significant interaction partner. Individually, neither PREX1 nor TOM1 associated with MGUS in this or in the earlier study [4] . If the role of PREX1 or TOM1 could be replicated in a larger interaction study the combined results could be explained with a model of higher enrichments of functional variants in the end disease. Additionally, SNPs marked by genes CEP120, CBX7, and RFWD3 were enriched in MM compared to MGUS.
In summary, the present GWAS on MGUS appears to be capable of delineating distinctions between MGUS and MM germlines. Associations with the PROX1, SFMBT, RAD51B, and CSNK1G1 loci were only found for MGUS, which may suggest that they are less important in the course of progression to MM. These genes have known functions in plasma cells and/or carcinogenesis, including homeobox transcription factor (PROX1) interacting with GATA2, chromatin remodeling through histone modification (SFMBT), double-stranded DNA repair (RAD51B), and cell cycle checkpoint arrest, DNA repair, and Wnt signaling (CSNK1G1). These are the functions that have been proposed to the SNPs identified in MM (chromatin remodeling, B-cell development, and cell cycle/genomic stability); additionally, apoptosis/autophagy pathways were suggested for MM for which we did not find evidence in MGUS [3] . The association with TNFRSF13 was stronger in MGUS compared to MM but the reverse was the case for the SNP forming the IRF4-binding site. PREX1 and TOM1 associations were only found in MM. If such distinctions can be verified in independent studies on MGUS they advance molecular understanding of the progression process, of the related prognostic markers and of the possible targets for intervention. Leukemia (2019) To the Editor:
The AML1-ETO fusion protein is produced by the t(8;21) translocation, which is the most common chromosomal abnormality in acute myeloid leukemia (AML). Although AML1-ETO alone is insufficient to cause leukemia, it is necessary for maintaining leukemia and therefore represents a therapeutic target. This notion has been supported by several lines of evidence: (i) transient suppression of AML1-ETO by small interfering RNA (siRNA) increases susceptibility of the leukemic cells to differentiation and delays leukemogenesis in vivo [1, 2] ; (ii) in a mouse model harboring fully developed leukemia, switching off AML1-ETO leads to leukemia regression [3] ; (iii) in an AML1-ETO9a (AE9a)-driven leukemic mouse model, myeloid differentiation of leukemic cells triggered by panobinostat (an HDAC inhibitor) was attributed to AE9a degradation [4] ; and (iv) mechanistic studies revealed that depletion of AML1-ETO in leukemic cells leads to a genome-wide epigenetic reprogramming and changes in transcription factor binding, resulting in myeloid differentiation and loss of leukemia maintenance [5] . We previously found that, in leukemic cells, AML1-ETO is stabilized and functions through the AML1-ETOcontaining transcription factor complex (AETFC), which contains multiple transcription (co)factors that include AML1-ETO, CBFβ, E proteins HEB and E2A, hematopoietic bHLH transcription factor LYL1, LIM domain protein LMO2 and its binding partner LDB1 [6] . These AETFC components mutually stabilize each other and cooperatively bind and regulate target genes, and AETFC integrity and proper conformation are essential for leukemogenesis [6] . Thus, destabilization of AETFC provides a strategy to target AML1-ETO. Notably, it has been generally proposed that the stability of a protein complex can These author contributed equally: Meng-Meng Zhang, Na Liu and Yuan-Liang Zhang Data deposition: The RNA-seq and ChIP-seq data have been deposited in the Gene Expression Omnibus (GEO) database and are accessible through GEO series number GSE114642. be reflected by its sensitivity to overexpression versus depletion of individual components [7] . First, many complexes can be destabilized by overexpression of individual components that, in a dosage-dependent manner, make promiscuous interactions that change the topology of the complex and thereby destabilize it. This mechanism, known as "dosage sensitivity", is widely applicable to the regulation of protein functions in organisms ranging from yeast to human [8] , including the interplay among the key transcription factors in hematopoiesis and leukemogenesis [9] . Second, other complexes show a lack of sensitivity (termed "robustness") to component overexpression, likely because they possess strong multivalent interactions that cannot be altered by dosage increase, but can be perturbed by depletion, of individual components [10] .
In this study, we investigated a means to destabilize AETFC, as well as the underlying mechanism. Following the principle described above, we first examined whether overexpression of AETFC components could affect the stability of the complex. In addition, several known interacting partners of AETFC components, including C/EBPα, TAL1, and ID1, were also analyzed. We transduced Kasumi-1 cells with retroviruses expressing HEB, E2A, E2-2, LDB1, LYL1, LMO2, C/EBPα, TAL1, or ID1 (Supplementary Figure S1a) , and determined the protein levels of each AETFC component by immunoblot. The results showed that overexpression of the AETFC components failed to destabilize the complex (Fig. 1a) . Thus, this result, in combination with our previous observation that knockdown of AETFC components in Kasumi-1 cells leads to degradation of the complex [6] , reflects the "robustness" of AETFC. This result is also consistent with the extremely strong biochemical stability of AETFC that we previously established [6] .
Unexpectedly, overexpression of C/EBPα dramatically decreased the protein levels of all AETFC components (Fig. 1a) and led to an accompanying inhibition of Kasumi-1 cell growth (Supplementary Figure S1b) . To verify the loss-of-function of AETFC, we performed RNA-seq of the cells. Gene set enrichment analysis (GSEA) revealed that previously identified [6] effects of AETFC-loss on both the up and downregulated target genes tend to be mimicked by C/EBPα overexpression; this was confirmed by RT-qPCR analysis of representative genes (Fig. 1b) . GSEA also revealed that the genes associated with myeloid differentiation are enriched, whereas those associated with hematopoietic stem cells are depleted, in the C/EBPα-activated genes (Supplementary Figure S2) , consistent with the function of C/EBPα in myeloid differentiation [11] . We next employed the AE9a-driven leukemic mouse model to investigate whether C/EBPα overexpression could affect leukemogenesis. We observed that C/EBPα overexpression induces myeloid differentiation of the mouse leukemia cells and delays leukemogenesis in vivo, as indicated by an increased frequency of CD11b + cells and a significantly extended survival time of the mice (Fig. 1c) . Thus, these results suggest that AETFC destabilization can be achieved by overexpression of C/EBPα, which is associated with cell differentiation and delayed leukemogenesis; however, the mechanism of how C/EBPα destabilizes AETFC is unclear. While C/EBPα has been shown to physically interact with AML1-ETO [12] , this interaction is relatively weak compared with the interactions among other factors (e.g., the interactions among AETFC components and the interactions of TAL1 and ID1 with E proteins), and thus is insufficient to mediate a "dosage sensitivity" effect that destabilizes AETFC [8] . We therefore examined whether C/EBPα overexpression can affect AETFC in other ways. Using RNA-seq and RT-qPCR, we found that C/EBPα overexpression leads to a significant decrease of LYL1 mRNA, but not other AETFC component mRNAs (Fig. 2a) . Our previous characterization of one-to-one interactions within AETFC revealed a central position of LYL1 (i.e., LYL1 interacts strongly with E proteins and LMO2 and weakly with AML1-ETO and LDB1) [6] . We thus speculated that loss of LYL1 could disrupt AETFC. To confirm this, we analyzed the integrity of AETFC in the presence and absence of LYL1 by co-immunoprecipitation (co-IP) assay, and we found that, if LYL1 is absent, LMO2 and LDB1 cannot be integrated into a complex with AML1-ETO and E proteins (Fig. 2b, i) . Thus, LYL1 appears to act as a linker for the AML1-ETO-E proteins (AE-E) and the LMO2-LDB1 parts of AETFC. This mechanism was held valid for the endogenous AETFC, as knockdown of LYL1 in Kasumi-1 cells led to reduced amounts of LMO2 and LDB1 that bind to AML1-ETO (Supplementary Figure S3 ). An analysis of Kasumi-1 nuclear extract indicated that knockdown of LYL1 led to a dramatic degradation of LMO2 and LDB1, as well as decreased HEB and E2A (Fig. 2b, ii) ; AML1-ETO was lagged behind in this degradation process likely due to a different degradation mechanism for AML1-ETO relative to other AETFC components. In contrast, knockdown of TAL1, a homologue of LYL1, did not show such an AETFC destabilization effect (Fig. 2b, ii) . Conversely, overexpression of LYL1 in the C/EBPα-overexpressed Kasumi-1 cells rescued AETFC stability, and the extent of restoration of different AETFC components correlates with the interaction strength and spatial distance between these components and LYL1 (Fig. 2b, iii) . Taken together, these results suggest that downregulation of LYL1 by C/EBPα contributes to the AETFC destabilization.
To investigate whether LYL1 is directly regulated by C/ EBPα and to gain a genome-wide view of C/EBPα binding, we performed a ChIP-seq analysis of the overexpressed C/ EBPα in Kasumi-1 cells. The results showed that C/EBPα directly binds to an~−1 kb region of the LYL1 locus (Fig. 2c, i) , which was confirmed by ChIP-qPCR (Fig. 2c,  ii) . Recently published ChIP-seq data also indicated that this region is physiologically bound by endogenous C/EBPα in myeloid cell lines (Supplementary Figure S4) . Interestingly, this −1 kb region is distinct from the previously reported promoter region (within 542 bp upstream of LYL1 transcription start site) bound by ETS and GATA factors [13] . C/EBPα is known mostly as a transcriptional activator and, according to our RNA-seq data, overexpressed C/EBPα in Kasumi-1 cells activates more genes relative to repressed genes (Supplementary Figure S5a) . However, it has also been established that C/EBPα can repress genes [14] (e.g., MYC, MYB, and GATA2), and we observed direct binding and downregulation of these genes by C/EBPα in Kasumi-1 cells (Supplementary Figure S5b and c) . To validate that C/EBPα directly represses LYL1 transcription, we performed a luciferase reporter assay and observed that the transcriptional activity of the LYL1 promoter is decreased upon C/EBPα overexpression in a dosage-dependent manner (Fig. 2c, iii) . Furthermore, GSEA revealed a strong Figure S6a) , suggesting that repression of LYL1 to some degree recapitulates the effect of C/EBPα overexpression. We next investigated whether LYL1 repression contributes to leukemic cell differentiation. We simultaneously overexpressed LYL1 and C/EBPα in Kasumi-1 cells and assessed their differentiation. The results showed that the LYL1 overexpression reduces the number of C/EBPα-induced CD11b
+ cells (Supplementary Figure S6b) . Furthermore, we observed that knockdown of LYL1 enhances the ability of Kasumi-1 cells to differentiate upon induction by Vitamin D3, which otherwise shows very subtle effect on the cells (Supplementary Figure S6c) . These results suggest that the LYL1 depletion can release the differentiation blockage in leukemic cells, although it is Figure S6c) . This insufficiency is likely because C/EBPα activates many genes required for myeloid differentiation, while LYL1 depletion and AETFC destabilization can release the repression of some genes but cannot fully activate them. In summary, our study first demonstrated an AETFC "robustness" in leukemic cells, which confer on the complex a resistance to a destabilization strategy based on overexpression of AETFC components. However, we found that overexpression of C/EBPα can destabilize AETFC by direct repression of the core component LYL1 at the transcriptional level, and that the depletion of LYL1 causes AETFC disruption that increases susceptibility of the leukemic cells to differentiation (Fig. 2d) . The important role of C/EBPα in t(8;21) leukemia development and treatment has been established [11] and recently re-emphasized by several interesting studies showing that depletion of AML1-ETO activates a C/EBPα-dominated transcriptional network [15] and that C/EBPα overrides the repressive activity of AML1-ETO [16] . Our studies provide a new mechanism by which C/EBPα can destabilize AETFC, suggesting restoration of C/EBPα as a strategy for leukemia therapy, and further identifying LYL1 as a new therapeutic target in t (8;21) leukemia. 
To the Editor:
About 20 recurrently mutated genes are known to be involved in the molecular pathogenesis of acute myeloid leukemia (AML) [1] . Among them, Nucleophosmin (NPM1) and FLT3-ITD mutations frequently occur together in adults with AML [2] , suggesting cooperative leukemogenesis. To date, the molecular consequences of these cooperative genetic alterations in AML are still elusive.
To address this issue, we crossed Npm1 and Flt3-ITD mutant mice demonstrating the onset of lethal AML (Fig. 1a and Figure S1) ) showed the higher white blood cell (WBC) counts, a significant spleen enlargement (Fig. 1a ii-iii) and developed AML rapidly regardless of NPM1 mutation dosage, suggesting that in the context of a high FLT3 kinase activity even small NPM1 mutant levels are leukemogenic. This supports a direct oncogenic effect of the NPM1 mutant, beside the haploinsufficient tumor suppressor effects of the concomitant loss of one NPM1 allele [3, 4] . Additionally, our data are in line with the clinical observation that normal karyotype AML with high FLT3-ITD levels have a poor outcome [5] .
The analysis of the Npm1 (Fig. 1b i-ii) .
Flow cytometry analysis of bone marrow (BM) populations showed that leukocytosis was associated to reduced long-term hematopoietic stem cells (HSCs), significant expansion of multipotent progenitor (MPP) cells and a 6.1-fold increase of granulocyte/monocyte progenitors (GMPs) (Fig. 1b iii-iv) . Npm1
+/TCTG
;Flt3 +/ITD mice had decreased number of immature and recirculating B-cell BM populations ( Figure S2 ). Erythrocyte changes reflected a significant reduction in the corresponding BM populations at different differentiation stages including myelo-erythroid progenitors (MEP), premegakaryocyte-erythrocyte progenitors (PreMegE), precolony forming unit-erythroid (pre-CFU-E), CFU-E and proerythroblasts (proEry) that resulted almost absent (Fig. 1b v-vi and Figure S3 ). In physiological hematopoiesis, FLT3 upregulation is important in sustaining MPP and GMP but not MEP potential [6] . In Npm1 ;Flt3 +/ITD BM samples displayed a significant deregulation of factors involved in megakaryocyte development and platelet production. Interestingly, several genes associated with this pathway were linked to a GATA transcriptional signature, including GATA1, Zpfm1, Rac1 and Ehd2. The latter showed a significant downregulation, with GATA1 displaying the lower levels ( Figure S4) . A similar expression signature was present in lineage-depleted BM cells used to exclude biases related to the different cellular composition of leukemic versus wild-type mice ( Figure S5 ). In this context, we found a higher number of deregulated GATA gene family members including GATA1, GATA2 and GATA3.
Results of GEPs and the presence of alterations in erythropoiesis before AML development prompted us to focus average of 78.1% ± 1.3 methylated CpG sites compared to 68.8% ± 2.6 in NPM1-mutated only, 69% ± 0.7 in FLT3-ITD-mutated only and 64% ± 3.1 in wild-type (Fig. 2b ii) . Finally, the analysis of GATA1 expression levels was performed in BM samples from 3 NPM1-mutated/FLT3-ITD patients treated with 5-Aza-dC, revealing a significant up-regulation of GATA1 mRNA after the first cycle (Fig. 2b iii) . These data corroborate a potential role for DNA methylation of GATA1 promoter in the development of NPM1-mutated/FLT3-ITD AML. Our findings are also of potential clinical relevance, as GATA1 transcriptional response to 5-Aza-dC in mice results in significant improvement of the myeloid phenotype. Similarly, we observed GATA1 mRNA up-regulation in two NPM1-mutated/FLT3-ITD AML patients upon 5-Aza-dC treatment.
In conclusion, we identified deregulation of GATA1 as a new feature of Npm1/Flt3-ITD AML in mice and humans. This is an early event altering the HSC fate and sensitizing cells to further malignant transformation. Our model may also be valuable for further assessment of FLT3 inhibitors [14] and other drugs that have been shown to be active against NPM1-mutated AML [15] .
